Breast cancer heterogeneity demands that prognostic models must be biologically driven and recent clinical evidence indicates that future prognostic signatures need evaluation in the context of early compared with late metastatic risk prediction. In pre-clinical studies, we and others have shown that various proteinprotein interactions, pertaining to the actin microfilament-associated proteins, ezrin and cofilin, mediate breast cancer cell migration, a prerequisite for cancer metastasis. Moreover, as a direct substrate for protein kinase Cα, ezrin has been shown to be a determinant of cancer metastasis for a variety of tumour types, besides breast cancer; and has been described as a pivotal regulator of metastasis by linking the plasma membrane to the actin cytoskeleton. In the present article, we demonstrate that our tissue imaging-derived parameters that pertain to or are a consequence of the PKC-ezrin interaction can be used for breast cancer prognostication, with inter-cohort reproducibility. The application of fluorescence lifetime imaging microscopy (FLIM) in formalin-fixed paraffin-embedded patient samples to probe protein proximity within the typically <10 nm range to address the oncological challenge of tumour heterogeneity, is discussed.
Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients Introduction
Breast cancer is the most common malignancy in women. Despite improving survival rates, the global burden of breast cancer remains high with approximately half a million breast cancer related deaths reported worldwide annually. A number of prognostic tools predicting the risk of metastatic relapse are used by oncologists to guide clinical decision-making [1, 2] . The accuracy of these prognostic models is far from perfect, and recent clinical evidence indicates that the traditional clinicopathological parameters (e.g. tumour size, lymph node status) used in prognostic models such as Adjuvant Online [1] or the St. Gallen's Consensus [2] may not correlate well with clinical outcome in some breast cancer subtypes [3, 4] . Similarly, although prognostic models using multigene signatures such as Mammaprint [5] or Oncotype Dx [6] have been shown to outperform clinicopathological parameterbased tools in predicting distant metastases [7] , a number of studies have also highlighted their shortcomings. Despite molecular estimation of high-risk disease in node-negative breast cancer patients by Oncotype Dx and Mammaprint, 69 % and 44 % of these patients, respectively, experienced long-term disease-free survival.
In recent years, next-generation sequencing approaches have demonstrated the cellular heterogeneity of tumours, comprising distinct subpopulations of cancer cells characterized by specific genomic profiles, and thereby representing the clonal evolution of that tumour [8] [9] [10] . In the present article, we focus on protein expression, post-translational modification and protein-protein interaction, and their functional consequences, which offer complementary information to the transcriptome, copy number variation (CNV) and mutational profiles in human breast cancer [11, 12] . Currently, the presence/absence of tissue protein markers such as oestrogen receptor (ER), human epidermal receptor 2 [HER2 (ErbB2)] and progesterone receptor (PgR); plus epidermal growth factor receptor (EGFR) status and at least one basal marker [cytokeratin (CK) 5/6], are used to predict cancer progression and guide treatment strategy [13] . Despite the use of these markers to guide stratification of treatment (e.g. anti-ER, HER2 or EGFR targeting inhibitors), the need for improved prognostic and predictive biomarkers remain. For instance, Santagata et al. [14] have recently suggested a new classification based on tissue quantification by multiplex immunofluorescence imaging-based detection of ER, vitamin D receptor (VDR), androgen receptor (AR), CK5 and the proliferation marker Ki67. They showed that this new classification, which is based on defining tumour subtypes according to their similarities with specific normal cell origin subtypes, can be used for disease prognostication.
In the present article, we describe a set of key optical proteomic parameters [15] pertaining to a protein subnetwork which is involved in regulating cancer cell motility, for predicting the time to cancer metastasis among heterogeneous breast cancer patient populations.
Protein kinase Cα (PKCα) in cancer development and metastasis
PKCα (a conventional PKC isoform) belongs to the family of protein kinases initially identified as phospholipid and calcium-dependent kinases [16] , which are involved in tumour promotion and progression as a response to stimulation with phorbol ester PMA [17] . More recently, this PKC isoform has been found to be important for maintaining the breast cancer stem cell population [18] . Downstream targets include Raf1 [19] which in turn activates extracellular-signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK) and nuclear factor κB (NF-κB) leading to increased transcription of metalloproteinase-9 and tumour cell migration [20] [21] [22] [23] . Among other targets for active PKCα, we have identified β1 integrin, fascin and ezrin [24] [25] [26] , which form signal complexes on the cell membrane and propagate the signal to the cytoskeleton, triggering a migratory response. Many other PKC targets exist within the motility pathway [27] but are outside the scope of the present article due to space constraints.
Ezrin and cofilin in cancer cell migration
Ezrin [belonging to the ezrin/radixin/moesin (ERM) family of proteins] and cofilin are actin-remodelling proteins playing different roles in reorganization of actin cytoskeleton which results in directional motility of the cell. ERM proteins and cofilin are linked in one gene/signalling network [28, 29] and their function depends on the presence of each other [30] . Ezrin expression was found to be necessary for metastasis [31] and its cytoplasmic or nuclear localization correlated with aggressiveness and lymph node positivity in human breast cancer [32, 33] . In addition to being a substrate for PKC [25] , it can also be activated by ER signalling via the c-Src pathway [34] . The phosphorylation/dephosphorylation cycle of cofilin also plays an important role in actin remodelling which is required for tumour cell protrusion [35] , and therefore cell invasive potential [36] [37] [38] . In addition to the ERM-cofilin association at a transcriptional level, ERM and the sodium/hydrogen exchanger 1 (NHE-1) have been shown to localize to cofilin-positive invadopodia in a talindependent manner to promote invadopodium maturation [39] . This physical association via talin therefore links these two important actin-remodelling proteins in a pathway that can trigger cancer invasiveness. A combined assessment of the activation of these two classes of proteins should provide synergistic information for clinical assessment of the risk of metastasis.
Development and application of imaging assays for prediction of clinical outcome
In pre-clinical studies, we and others have shown that various protein-protein interactions, pertaining to the actin microfilament-associated proteins, ezrin and cofilin, mediate breast cancer cell migration, a prerequisite for cancer metastasis [25, 35, 36, 38, 40, 41] . There is no robust platform to measure these interactions in large-scale clinical sample sets. Our automated imaging platform [42] measures FRET, via the decrease in donor lifetime (reviewed in [43] ), by fluorescence lifetime imaging microscopy (FLIM), to directly monitor validated protein-protein interactions [24, 26, 44, 45] and post-translational modifications that include conformational changes, in cultured cells [24, [46] [47] [48] [49] [50] . A two antibody FRET/FLIM assay to measure endogenous protein-protein interactions (PKC-ezrin) in archived pathological material was developed together with new fluorescence-based assays for measuring the phosphorylation and subcellular localization of ezrin and cofilin (Figures 1 and 2 ). We hypothesized that these protein interaction/localization-based assays can generate useful information for predicting the likelihood of metastasis due to the biological function pertaining to these cytoskeleton-remodelling molecules. Specific FLIM-based ezrin-PKCα-protein interaction detected in formalin-fixed paraffin-embedded (FFPE) tissues Two-( Figure 1A ) and single-( Figure 1B ) photon excitationbased acquisition of intermolecular FRET efficiency detected specific protein-protein interactions between ezrin and PKC (see the FLIM/FRET images of invasive breast carcinoma samples that were labelled with fluorescently conjugated anti-ezrin IgG and anti-activated PKCα IgG). Comparison of the corresponding FRET efficiencies measured with either two-or single-photon excitation found no significant difference between the two lifetime acquisition methods and therefore single-photon excitation was chosen to acquire the subsequent FLIM data. Although the immune/inflammatory cell infiltrate (see white arrow in Figure 1B ) was autofluorescent, this contributed little (since the number of pixels/area was small proportionally) to the overall mean fluorescence lifetime per tumour. Similarly, the non-specific nuclear staining of the acceptor fluorophore-labelled antibody (antiactivated PKCα IgG) did not interfere with the determination of FRET by FLIM [51, 52] , which is based on the shortening of donor fluorescence lifetime of the donor fluorophore used to label the anti-ezrin IgG.
Subcellular protein localization and/or phosphorylation quantification
Ezrin-PKCα protein complex formation should result in downstream molecular events such as ezrin phosphorylation, redistribution and stabilization at the membrane [25] . Figures 1 and 2 show ezrin stabilization at the membrane ( Figures 1C and 1D) , with concomitant ERM phosphorylation ( Figure 2A ) and activation of PKCα (as shown by Thr 250 phosphorylation [53] , Figure 1D ), preferentially at the membrane of invasive breast carcinoma cells (see white arrow). The subcellular localization of proteins in tissue microarray cores was further quantified by automated image segmentation (AIS) and a manual scoring system. Nine image parameters for the subcellular distribution of ezrin ( Figure 1C ) across heterogeneous breast tumours were generated in less than 5 s by AIS. The parallel 'manual' scoring system ( Figure 1D ) generated five parameters, describing the subcellular compartment expression levels of both ezrin and PKCα in each tissue core. Further automated co-localization analyses demonstrated an increase in the total ezrin/phospho-ERM and cofilin/phospho-cofilin co-localization intensity at the cell-cell borders and/or edges of invasive tumour cells (Figures 2A and 2B ).
Selection of a consensus set of imaging-based covariates for a metastatic predictive model
We next established that the non-FRET-based image parameters (AIS or manual score) pertaining to ezrin and PKC were associated with FRET positivity, which is a measure of ezrin-PKCα interaction. Ezrin-PKCα protein complex formation influences downstream molecular events such as ezrin phosphorylation, redistribution and stabilization at the membrane, which are measured by the non-FRET-based image parameters [25] . Using single-photon FLIM-derived FRET positivity (>0 %) to define a binary outcome, a support vector machine (SVM) [54] predicted FRET positivity using a combination of the ezrin distribution (AIS and manual score) and phosphorylation parameters to an accuracy of ∼65 % ( Figure 3A) . A degree of overfitting was apparent when > four covariates were used to build the SVM.
Next, two independent breast cancer cohorts were imaged for cofilin/phospho-cofilin and ezrin/phospho-ezrin colocalization, along with ezrin localization analysis using AIS (88 patient samples from the 1980s series and a total of 134 patient samples from the 1990s series were available for evaluation). There is a high degree of heterogeneity between the two cohorts (the adjuvant treatments for the two cohorts differed significantly: 1980s compared with 1990s; chemotherapy 0 % compared with 30 %; endocrine 36 % compared with 76 %, respectively). In exploratory univariate analysis, the upper quartile of cofilin/phosphocofilin co-localization intensities was associated with early distant metastasis among patients with reported relapse [ Figure 3B ; upper quartile (n = 17) compared with lower values (n = 52); P = 0.022, log-rank test]. This was not the case for ezrin/phospho-ezrin co-localization ( Figure 3C) ; furthermore, exploratory analysis of lower and upper quartiles indicated that lower quartile ezrin/phospho-ERM co-localization may be associated with poorer distant metastasis-free survival in the 1980s series ( Figure 3D ; P = 0.098, not significant, log-rank test) but not the 1990s series ( Figure 3E ; P = 0.73, not significant, log-rank test).
The predictive accuracy of all 18 covariates (16 imaging parameters, Figures 1C and 1D , and whether or not the patient had received treatments: tamoxifen or chemotherapy) was assessed for distant metastasis-free survival using a Bayesian proportional hazards regression model with crossvalidation for the two temporal cohorts (1980s and 1990s). A step-down procedure was used to iteratively reduce the number of covariates in the model, and over-fitting was observed when greater than six covariates were used to build the model. The top six covariates were identified for the 1980s and 1990s (relapse) cohorts. The predictive accuracy (both training and validation) for 7-year distant metastasis-free survival in the 1980s cohort is shown in Figures 3(F) 
and 3(G).
There was an overlap between the top four covariates in the SVM analysis for FRET positivity ( Figure 3A) , and the two separate lists of the top six covariates for predicting metastatic relapse. On the basis of this overlap with SVM analysis, a final consensus set of six covariates (average membrane intensity, relative and absolute; cytoplasm average intensity and number of pixels inside cytoplasm, manual ezrin cytoplasm score and membrane length) was selected and confirmed by re-running the Bayesian proportional hazards regression against each of the two patient cohorts. For the 1980s cohort, the model predicted 7-year distant metastasis-free survival to an accuracy of up to ∼70 % ( Figure 3H) . The same consensus set of covariates was found to be predictive for early relapse (within 3 years) among patients with reported distant metastases in the 1990s cohort ( Figure 3I ).
Conclusions
The remarkable diversity in breast cancer dictates that prognostic models must be biologically driven. We describe the first optical imaging-based tumour metastatic signature, measuring underlying biological variables which are pertinent in tumour metastases. Our semi-automated tissue imaging platform is capable of performing an integrated analysis of protein phosphorylation, protein-protein interaction and subcellular protein expression/distribution, using FFPE tissue microarrays. Incorporation of protein interaction data was shown to also improve the predictive performance of prognostic gene expression signatures [55, 56] . Despite the importance of adjunct information supplied by the protein interactome configuration to improve the existing prognostic signatures for predicting patient outcome [56] , this protein interaction information has rarely been incorporated in diagnostic/prognostic assays.
We report that our imaging parameters could predict the metastatic risk for early breast cancer patients with a high level of accuracy (∼70 %; Figure 3 ). Moreover, reproducibility across different temporal cohorts, a prerequisite for any prognostication model to use in 'real life' patients, is achieved with our new multivariate, imaging-based metastatic signature. Although prospective validations of prognostic tools are imperative, our study is among the first to compare how well a predictive/prognostic signature performs, between patient cohorts that belong to two time periods (i.e. 1980s compared with 1990s). The clinical implications of this protein network/function-based design, alongside our key points of parameter reduction and time-dependent risk assessment, are likely to provide a novel tool that may be of generic utility not only for future prognostic models but also for studying the effects of different signalling pathways on clinical outcome with the eventual goal of individualization of cancer care. We aim to prospectively investigate the use of our new integrated biomarker platform to delineate and quantify relevant oncogenic protein complexes in clinical specimens within a clinical trial setting.
This new paradigm is likely to be key to improving our understanding of tumour biology and factors relating to recurrence and metastasis as well as characterizing patients for the eventual goal of treatment individualization.
